Our mission is to provide comprehensive personalized molecular solutions to inform cancer care.
NantOmics, a member of the NantWorks ecosystem of companies, is a leader in molecular diagnostic testing and the first company to employ an integrated panomic approach to inform personalized treatment options for patients with cancer. Combining DNA sequencing, RNA sequencing, and quantitative proteomics, NantOmics offers extensive testing capabilities that provide a comprehensive molecular profile of a patient’s cancer. Our proprietary analytical platform delivers molecular diagnostic capabilities that provide actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care.
Charlie Vaske, PhD
Steve Benz, PhD
Shahrooz Rabizadeh, PhD
Bobby Reddy, MD
Dr. Sandeep “Bobby” Reddy is NantHealth’s Chief Medical Officer. Dr. Reddy joined NantHealth in December of 2016 to oversee educational initiatives, outreach, clinical development programs, and clinical trials for GPS Cancer—NantHealth’s proprietary precision medicine cancer analytic platform. Since